动脉插管化疗合并放疗治疗晚期和巨块型宫颈癌  

Concurrent Arterial Catheter Chemotherapy and Radiotherapy for Advanced and Bulky Cervical Cancer

作　　者：丁云霞[1] 陈宏[1] 刘跃[1] 王永刚[1] 徐云霞[1] 

机构地区：[1]成都军区昆明总医院肿瘤科,650032

出　　处：《实用癌症杂志》2002年第1期77-79,共3页The Practical Journal of Cancer

摘　　要：目的　评价动脉插管化疗加放疗治疗晚期及巨块型宫颈癌的疗效。方法　将 68例巨块型宫颈癌及 78例晚期宫颈癌随机分为 2个组 ,各 73例。A组采用腹壁下动脉或股动脉插管化疗 (顺铂、氟脲嘧啶及丝裂霉素化疗 3个周期 )加放疗 ;B组为单纯放疗。 2组放疗均为外照射加腔内照射。结果　A组的 3年生存率 (78.0 8% ,P <0 .0 5 )高 ,局部复发率 (17.81% ,P <0 .0 5 )低 ,A、B 2组远处转移率及直肠膀胱并发症发生率无显著性差异。A组中 2种插管法的治疗效果无显著性差异。结论　动脉插管化疗合并放疗治疗晚期及巨块型宫颈癌 ,可提高生存率 ,降低局部复发率 。Objective To evaluate the therapeutic effects of arterial chemotherapy and radiotherapy for advanced and bulky cervical cancer.Methods 78 patients with advanced cervical cancer stage Ⅲ Ⅳ and 68 patients,with local bulky cervical cancer ≥4 cm in tumor diameter,were divided randomly to therapy group(TG) and radiotherapy alone group(RG).Cisplatin,fluorouracil and mitomycin were administrated by transcatheter arterial infusion through inferior epigastric or femoral artery in TG.The first cycle chemotherapy was administrated before radiation,the other two cycles were administrated during radiation in TG.The style and dose of radiotherapy was similar in two groups,external beam and intracavitary radiation.Results The median duration of follow up was 52.6 months.The survival rate was higher in TG(78.08%) than in RG, P <0.05.The rate of locoregional recurrence was lower in TG(17.81%) than in RG, P <0.05.There was not significantly difference in distant metastases and the late complications of rectum and bladder between two groups.There was no significantly difference in curative effect between two arterial chemotherapy of TG.Conclusion Regimens of radiotherapy and artrial chemotherapy combination,containing cisplatin,fluorouracil and mitomycin C,may improve the survival and locoregional recurrence rates in advaced and local bulky cervical cancer,but do not decrease distant metastases rate.The adverse reactions are mild in TG.

关 键 词：宫颈癌 晚期 巨块型 动脉插管化疗 疗效 放射疗法 治疗 

分 类 号：R737.33[医药卫生—肿瘤] R730.5[医药卫生—临床医学]